Corbus Pharmaceuticals Holdings is focused on the development of immune modulators that will have application in disease states spanning from immuno-oncology to fibrosis. Co.'s pipeline includes anti-integrin monoclonal antibodies that block activation of Transforming growth factor B (TGFB) and small molecules that activate or inhibit the endocannabinoid system. Co.'s pipeline includes: anti-integrin monoclonal antibodies for the treatment of cancer and fibrosis that inhibit the activation of TGFB; cannabinoid receptor type 1 inverse agonists designed to treat obesity and related metabolic diseases; and lenabasum, a synthetic, oral molecule that activates cannabinoid receptor type 2. The CRBP average annual return since 2014 is shown above.
The Average Annual Return on the CRBP average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CRBP average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CRBP average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free CRBP Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
